title: Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.
abstract: There is an urgent need to identify relevant tumor markers showing high sensitivity and specificity for early immunodiagnosis of breast cancer. Autoantibodies directed against tumor-associated antigens (TAAs) have been shown to be relevant tumor markers. The purpose of this study was to evaluate whether autoantibodies to a tumor-associated antigen p90/CIP2A can be used as diagnostic markers in breast cancer. In this study, autoantibody responses to p90/CIP2A were evaluated by enzyme-linked immunosorbent assay (ELISA), western blotting, and indirect immunofluorescence assay in sera from patients with breast cancer and normal human individuals. The results have demonstrated that p90/CIP2A can induce a relatively higher frequency of autoantibody response in breast cancer (19.1%) compared to the sera of normal individuals (2.3%). The frequency of p90/CIP2A expression in breast cancer tissues was significantly higher than that in adjacent normal tissues (P < 0.01). Our preliminary results suggest that autoantibodies against p90/CIP2A may be a useful serum biomarker for early stage breast cancer screening and diagnosis.
authors.affiliation: College of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Liu
authors.forename: Yurong
authors.initials: Y
authors.lastname: Chai
authors.forename: Jitian
authors.initials: J
authors.lastname: Li
authors.forename: Pengfei
authors.initials: P
authors.lastname: Ren
authors.forename: Mei
authors.initials: M
authors.lastname: Liu
authors.forename: Liping
authors.initials: L
authors.lastname: Dai
authors.forename: Wei
authors.initials: W
authors.lastname: Qian
authors.forename: Wenjie
authors.initials: W
authors.lastname: Li
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood; D001324:Autoantigens / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000097:blood / Q000276:immunology*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins / Q000276:immunology*; D046888:Tissue Array Analysis
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; C500266:CIP2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins